A new prospective multicenter study published in Dermatology and Therapy finds that Castle Biosciences' DecisionDx-Melanoma i31-SLNB test more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity in cutaneous melanoma than the Melanoma Institute Australia (MIA) nomogram. The i31-SLNB test showed a 2.6% SLN positivity rate for low-risk patients, below the 5% threshold for avoiding biopsy, compared to 5.8% for the MIA nomogram, which failed to identify patients below this threshold. This improved accuracy supports better clinical decision-making on whether to perform sentinel lymph node biopsy, potentially reducing unnecessary surgeries and complications. The study reinforces the value of integrating tumor biology with clinical factors for personalized melanoma care.
Woodward, Inc. announced a quarterly cash dividend of $0.32 per share, payable on September 3, 2026, to shareholders of record as of August 20, 2026. This dividend reflects the company's ongoing commitment to returning value to shareholders. Woodward...
EShallGo Inc., a provider of integrated office technology solutions, completed a $1.479 million registered direct offering by selling 454,968 Class A shares at $3.25 each. The funds will support its growth in AI-enabled enterprise applications launch...
MEDIROM MOTHER Labs has expanded its deployment of the REMONY® remote health monitoring system, equipped with the recharge-free MOTHER Bracelet®, in the Japan Ground Self-Defense Force (JGSDF) 8th Division. The additional order triples the scale of t...
A new playground designed by kids and built by volunteers opened at Chimborazo Elementary School in Richmond, serving over 400 students and the wider community. Funded mainly by the CarMax Foundation and supported by KABOOM!, this project aims to add...
Equinox Gold has signed 20-year land access agreements with the three communities hosting its Los Filos Mine in Mexico, enabling the company to begin restarting heap leach operations and advancing technical studies for potential expansion, including ...
